iPSC-derived Allogeneic Cancer Immunotherapies
Cancer
Pre-clinicalActive
Key Facts
About Plasticell
Plasticell is a private biotechnology company pioneering a high-throughput combinatorial screening platform, CombiCult®, to rapidly develop optimized cell culture protocols for regenerative medicine. Its therapeutic pipeline is centered on advanced cell and gene therapies, including iPSC-derived allogeneic cancer immunotherapies, hematopoietic stem cell expansion, and treatments for thrombocytopenia and anemia. The company operates through a collaborative business model, partnering with academic and industry leaders like Imperial College London and the Cell and Gene Therapy Catapult to advance its programs and manufacturing capabilities.
View full company profileTherapeutic Areas
Other Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| Not Specified (Oncology Focus) | Narwhal Bio | Pre-clinical |
| EDM Platform for Genetic Medicine | Coastar Therapeutics | Pre-clinical |
| CO-1 | Caedo Oncology | Pre-clinical |
| Anti-CD99 monoclonal antibody | Caedo Oncology | Discovery/Pre-clinical |
| Anti-HLA class I monoclonal antibody | Caedo Oncology | Discovery/Pre-clinical |
| Triapine® | Nanopharmaceutics | Clinical |
| Ammonium Tetrathiomolybdate | Nanopharmaceutics | Clinical |
| Aza-TdC | Nanopharmaceutics | Clinical |
| Undisclosed Oncology Program(s) | Cell BioEngines | Phase 1 |
| No-alpha IL-2 Mutein | SarcoMed USA | Pre-clinical |
| PMIS Therapeutic | NaturemiRI | Preclinical/Clinical (unspecified) |
| AUM302 (formerly IBL-302) | Inflection Biosciences | Pre-clinical (partnered) |